Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 820 Show results per page	View Search Criteria \| Help With Results


1.		A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Closed				18 and over				Pharmaceutical / Industry				ML18527 NCT00121836

Last Modified: 11/1/1995


2.		Phase II/III Randomized Study of a New Paclitaxel Formulation Given by 3-Hour vs 96-Hour Infusion in Women with Refractory Metastatic Breast Cancer (Summary Last Modified 11/95)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				any age				Other				MAOP-1195 NCI-V95-0749

Last Modified: 12/1/1995


3.		Phase III Study of a 3-Hour Infusion of a New Paclitaxel Product in Refractory Ovarian Cancer, with a Phase II Crossover to a 96-Hour Infusion at Progression (Summary Last Modified 12/95)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				18 and over				Other				MAOP-7195 NCI-V95-0750

Last Modified: 5/31/2007 First Published: 7/1/1999


4.		Phase II/III Randomized Study of Paclitaxel and Carboplatin With or Without SCH 58500 in Patients with Newly Diagnosed Stage III Ovarian Epithelial or Primary Peritoneal Cancer With No Greater Than 2 cm Residual Disease Following Surgery (Summary Last Modified 07/2001)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Completed				18 and over				Pharmaceutical / Industry				SPRI-C/I98-102 SPRI-C98-102, NCI-V99-1544, NCT00003880

Last Modified: 6/20/2008 First Published: 9/1/2000


5.		Phase II/III Randomized Study of Paclitaxel and Carboplatin With or Without BMS-275291 in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				18 and over				Pharmaceutical / Industry				CAN-NCIC-BR18 BMS-CA161-003, NCT00006229, BR18

Last Modified: 6/3/2008 First Published: 7/1/2001


6.		Phase II/III Randomized Study of Paclitaxel and Carboplatin With or Without Bevacizumab in Patients With Advanced, Metastatic, or Recurrent Non-Squamous Cell Non-Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				18 and over				NCI				ECOG-4599 CALGB-E4599, E4599, NCT00021060

Last Modified: 5/10/2007


7.		Phase II/III Randomized Trial of DOX vs TAX vs DOX/TAX/G-CSF in Patients with Metastatic Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Completed				any age				NCI				E-1193 NCCTG-923252, SWOG-9332, E-10292, E1193

Last Modified: 5/20/2008 First Published: 10/21/2005


8.		Phase II/III Randomized Study of Paclitaxel and Carboplatin With Versus Without AZD2171 in Patients With Stage IIIB or IV Non-Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				18 and over				Other, Pharmaceutical / Industry				CAN-NCIC-BR24 ZENECA-CAN-NCIC-BR24, NCT00245154, BR24, FHCRC-6107, UWCC-UW 6107, UWCC- 06-2707-H/B


9.		Weekly Taxol Plus Xeloda® vs Taxotere q3wk Plus Xeloda® in the Treatment of Metastatic BC

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Completed				18 and over				Other				NBCG10 REK 378-04-03133, NMA 03-07568, NCT00201435


10.		A Phase II Trial Neoadjuvant Paclitaxel and Cisplatin in Patients With Locally Advanced Head and Neck Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Completed				18 to 75				Pharmaceutical / Industry				CA139-384 NCT00337532

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute